Cargando…

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8(+) and CD4(+) T-cell-mediated antitumor immunity and enhanced anti-PD1 responses

BACKGROUND: The tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which subverts T-cell immunity at multiple levels, is itself subject to inherent T-cell reactivity. This intriguing deviation from central tolerance has been interpreted as counterbalancing IDO1-mediated immunosuppr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dey, Souvik, Sutanto-Ward, Erika, Kopp, Katharina L, DuHadaway, James, Mondal, Arpita, Ghaban, Dema, Lecoq, Inés, Zocca, Mai-Britt, Merlo, Lauren M F, Mandik-Nayak, Laura, Andersen, Mads Hald, Pedersen, Ayako Wakatsuki, Muller, Alexander J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373332/ https://www.ncbi.nlm.nih.gov/pubmed/32690770 http://dx.doi.org/10.1136/jitc-2020-000605

Ejemplares similares

Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
por: Merlo, Lauren M. F., et al.
Publicado: (2020)

IDO1 is an Integral Mediator of Inflammatory Neovascularization
por: Mondal, Arpita, et al.
Publicado: (2016)

IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
por: Nandre, Rahul, et al.
Publicado: (2022)

CD4 responses against IDO
por: Andersen, Mads Hald
Publicado: (2012)

Impact of IDO1 and IDO2 on the B Cell Immune Response
por: Merlo, Lauren M. F., et al.
Publicado: (2022)

CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment
por: Lecoq, Inés, et al.
Publicado: (2022)

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2021)

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2022)

IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity
por: Merlo, Lauren M.F., et al.
Publicado: (2016)

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
por: Metz, Richard, et al.
Publicado: (2012)

IDO2 in Immunomodulation and Autoimmune Disease
por: Prendergast, George C., et al.
Publicado: (2014)

Type 17 immunity promotes the exhaustion of CD8(+) T cells in cancer
por: Kim, Byung-Seok, et al.
Publicado: (2021)

CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma
por: Lai, Chester, et al.
Publicado: (2021)

Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist
por: Upadhyaya, Punit, et al.
Publicado: (2021)

BRCA1 deficiency in mature CD8(+) T lymphocytes impairs antitumor immunity
por: Wu, Bogang, et al.
Publicado: (2023)

IDO1 and inflammatory neovascularization: bringing new blood to tumor-promoting inflammation
por: Muller, Alexander J., et al.
Publicado: (2023)

Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML
por: Herbrich, Shelley, et al.
Publicado: (2021)

Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response
por: Stirling, Elizabeth R, et al.
Publicado: (2022)

Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
por: Klaver, Yarne, et al.
Publicado: (2020)

Antimetabolite TTL-315 selectively kills glucose-deprived cancer cells and enhances responses to cytotoxic chemotherapy in preclinical models of cancer
por: DuHadaway, James, et al.
Publicado: (2016)

Cancer-Associated Fibroblasts Suppress CD8(+) T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade
por: Jenkins, Liam, et al.
Publicado: (2022)

RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus
por: Mandik-Nayak, Laura, et al.
Publicado: (2017)

TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer
por: Perez-Penco, Maria, et al.
Publicado: (2022)

Vaccination with post-translational modified, homocitrullinated peptides induces CD8 T-cell responses that mediate antitumor immunity
por: Shah, Sabaria, et al.
Publicado: (2023)

Systemic Immune Response in Murine Bilateral Pheochromocytoma Model During Immunotherapy Based on a Combination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibodies (MBTA Therapy)
por: Uher, Ondrej, et al.
Publicado: (2021)

Amino acids and RagD potentiate mTORC1 activation in CD8(+) T cells to confer antitumor immunity
por: Zhang, Yiwen, et al.
Publicado: (2021)

NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division
por: Borst, Linda, et al.
Publicado: (2021)

Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation
por: Deng, Guoliang, et al.
Publicado: (2022)

MDSC subtypes and CD39 expression on CD8(+) T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC
por: Koh, Jiae, et al.
Publicado: (2020)

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells
por: Munir, Shamaila, et al.
Publicado: (2013)

Spontaneous CD4(+) and CD8(+) T‐cell responses directed against cancer testis antigens are present in the peripheral blood of testicular cancer patients
por: Pearce, Hayden, et al.
Publicado: (2017)

Small molecule AZD4635 inhibitor of A(2A)R signaling rescues immune cell function including CD103(+) dendritic cells enhancing anti-tumor immunity
por: Borodovsky, Alexandra, et al.
Publicado: (2020)

CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity
por: Zammarchi, Francesca, et al.
Publicado: (2020)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

Immunization with short peptide particles reveals a functional CD8(+) T-cell neoepitope in a murine renal carcinoma model
por: He, Xuedan, et al.
Publicado: (2021)

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
por: Mortensen, Rasmus Erik Johansson, et al.
Publicado: (2023)

B-Cell-Targeted 3DNA Nanotherapy Against Indoleamine 2,3-Dioxygenase 2 (IDO2) Ameliorates Autoimmune Arthritis in a Preclinical Model
por: Merlo, Lauren MF, et al.
Publicado: (2020)

Saponin-based adjuvants enhance antigen cross-presentation in human CD11c(+) CD1c(+) CD5(−) CD163(+) conventional type 2 dendritic cells
por: Ho, Nataschja I, et al.
Publicado: (2023)

Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity
por: Xi, Qing, et al.
Publicado: (2020)

Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy
por: Jacoberger-Foissac, Celia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ihk1795ce9rf73tk8ajscvpd0r